The ACER-study - the effects of galantamine on the variability and stability of walking among patients with Alzheimer's disease.

Withdrawn

Conditions: 10027667
10012272
Alzheimer's disease
dementia

Registration Number: NL-OMON35628

Lead Sponsor: Slotervaartziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Withdrawn

Sex: Not specified

Target Recruitment: 60

Inclusion Criteria

Patients will be included for the present study when they are (a) aged 65 years or older; (b) diagnosed with mild to moderate Alzheimer's disease (according to the criteria of the DSM-IV and the NINCDS-ADRDA); and (c) able to walk for at least 160 meter without using any assistive device.

Exclusion Criteria

Patients will be excluded from the present study when they (a) have had any treatment with acetylcholine esterase inhibitors during the three months before inclusion; (b) have any mobility problems due to (lateral) neurological or orthopedic disorders with function limitations of one or both legs; (c) have severe visual impairments; or (d) are unable to understand and follow simple verbal instructions.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The outcome variables of three balance assessments with accelerometry (with and<br /><br>without dual-task) the 160-meter walking test, the Timed Up & Go test (TUG),<br /><br>and the FICSIT-4 test.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcome measures are: visual reaction time (indicator for attention),<br /><br>cognition (Mini Mental State Examination, 7 Minute Screen, Frontal Assessment<br /><br>Battery, STROOP color word test, and Digit Span), activities of daily living<br /><br>(by IDDD), and fall events.</p><br>